S&P 500

5.316,54

0,16%

Negocie como um profissional: Aproveite discussões em tempo real e ideias que movimentam o mercado para superar a concorrência.

Cadastre-se

Início
Investir
Ações
EUA
AMEX
AIM ImmunoTech Inc (AIM)
AIM ImmunoTech Inc (AIM) Notícias

AIM

AIM ImmunoTech (AIM)

AIM ImmunoTech Inc

De:

Notícias regulamentadas

Procure um Texto:

Ordenação:

Notícias não regulamentadas

Apresentando as notícias mais relevantes sobre:AMEX:AIM

1 2 3 4 5 6 7 8 9 10 Próxima >>

Data	Hora	Fonte	Título	Código	Companhia
20/05/2024	10:15	GlobeNewswire Inc.	AIM ImmunoTech to Participate in Two Upcoming Investor Conferences	AMEX:AIM	AIM ImmunoTech Inc
16/05/2024	08:30	GlobeNewswire Inc.	AIM ImmunoTech Reports First Quarter 2024 Financial Results and Provides Corporate Update	AMEX:AIM	AIM ImmunoTech Inc
15/05/2024	17:31	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	AMEX:AIM	AIM ImmunoTech Inc
09/05/2024	09:50	GlobeNewswire Inc.	AIM ImmunoTech to Discuss First Quarter 2024 Financial Results on May 16, 2024, and Host Conference Call and Webcast	AMEX:AIM	AIM ImmunoTech Inc
07/05/2024	09:30	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	AMEX:AIM	AIM ImmunoTech Inc
06/05/2024	09:30	GlobeNewswire Inc.	AIM ImmunoTech Completes cGMP Manufacturing of Clinical Vials of Ampligen®	AMEX:AIM	AIM ImmunoTech Inc
29/04/2024	09:55	GlobeNewswire Inc.	AIM ImmunoTech Announces First Dose Level is Generally Well-Tolerated in Phase 1b/2 Study of Ampligen and Imfinzi as a Combination Therapy for Late-Stage Pancreatic Cancer	AMEX:AIM	AIM ImmunoTech Inc
25/04/2024	09:45	GlobeNewswire Inc.	AIM ImmunoTech Announces Release of the Next CEO Corner Segment	AMEX:AIM	AIM ImmunoTech Inc
15/04/2024	09:55	GlobeNewswire Inc.	AIM ImmunoTech Announces Charles Lapp, MD, as a Consulting Medical Officer for its ME/CFS and Long COVID Programs	AMEX:AIM	AIM ImmunoTech Inc
10/04/2024	09:21	GlobeNewswire Inc.	AIM ImmunoTech Announces Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen Combined with Pembrolizumab for the Treatment of Recurrent Ovarian Cancer	AMEX:AIM	AIM ImmunoTech Inc
02/04/2024	08:30	GlobeNewswire Inc.	AIM ImmunoTech Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update	AMEX:AIM	AIM ImmunoTech Inc
28/03/2024	09:05	GlobeNewswire Inc.	AIM ImmunoTech to Present at the MedInvest Biotech & Pharma Investor Conference	AMEX:AIM	AIM ImmunoTech Inc
26/03/2024	10:05	GlobeNewswire Inc.	AIM ImmunoTech to Discuss Fourth Quarter and Full Year 2023 Financial Results on April 2, 2024, and Host Conference Call and Webcast	AMEX:AIM	AIM ImmunoTech Inc
25/03/2024	10:05	GlobeNewswire Inc.	AIM ImmunoTech Announces Publication of Positive Findings from a Study Evaluating Ampligen® in the Treatment of Pancreatic Cancer in the Journal Clinical Cancer Research	AMEX:AIM	AIM ImmunoTech Inc
15/03/2024	09:45	GlobeNewswire Inc.	AIM ImmunoTech to Participate in the Virtual Investor Lunch Break: The AIM Opportunity	AMEX:AIM	AIM ImmunoTech Inc
07/03/2024	10:45	GlobeNewswire Inc.	AIM ImmunoTech Announces Launch of CEO Corner Platform	AMEX:AIM	AIM ImmunoTech Inc
29/02/2024	10:45	GlobeNewswire Inc.	AIM ImmunoTech Outlines Recent Progress Across Clinical Development Pipeline and Provides Business Update	AMEX:AIM	AIM ImmunoTech Inc
21/02/2024	12:37	Edgar (US Regulatory)	Form D/A - Notice of Exempt Offering of Securities: [Amend]	AMEX:AIM	AIM ImmunoTech Inc
20/02/2024	18:34	Edgar (US Regulatory)	Form D - Notice of Exempt Offering of Securities	AMEX:AIM	AIM ImmunoTech Inc
20/02/2024	18:31	Edgar (US Regulatory)	Form 8-K - Current report	AMEX:AIM	AIM ImmunoTech Inc
14/02/2024	10:55	GlobeNewswire Inc.	AIM ImmunoTech Announces First Subject Dosed in the Netherlands for Phase 1b/2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi (durvalumab) for the Treatment of Pancreatic Cancer	AMEX:AIM	AIM ImmunoTech Inc
08/02/2024	10:50	GlobeNewswire Inc.	AIM ImmunoTech Reports Positive Topline Results from Phase 2 Study Evaluating Ampligen® for the Treatment of Post-COVID Conditions	AMEX:AIM	AIM ImmunoTech Inc
24/01/2024	11:10	GlobeNewswire Inc.	AIM ImmunoTech Receives Erasmus Medical Center Ethics Board Authorization for Phase 2 Study of Ampligen® for the Treatment of Locally Advanced Pancreatic Cancer	AMEX:AIM	AIM ImmunoTech Inc
22/01/2024	10:55	GlobeNewswire Inc.	AIM ImmunoTech Announces that the First Subject is Enrolled in the Phase 1b/2 Study Evaluating Ampligen® in Combination with AstraZeneca’s Imfinzi® for the Treatment of Late-Stage Pancreatic Cancer	AMEX:AIM	AIM ImmunoTech Inc
10/01/2024	10:45	GlobeNewswire Inc.	AIM ImmunoTech Announces Open Enrollment for Phase 1b/2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi® (durvalumab) for the Treatment of Pancreatic Cancer	AMEX:AIM	AIM ImmunoTech Inc
05/01/2024	15:32	Business Wire	AIM Shareholders Elect All Four Company Director Nominees at 2023 Annual Meeting	AMEX:AIM	AIM ImmunoTech Inc
03/01/2024	18:24	Edgar (US Regulatory)	Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]	AMEX:AIM	AIM ImmunoTech Inc
03/01/2024	18:24	Edgar (US Regulatory)	Form DFAN14A - Additional definitive proxy soliciting materials filed by non-management and Rule 14(a)(12) material	AMEX:AIM	AIM ImmunoTech Inc
03/01/2024	18:05	PR Newswire (US)	Kellner Seeking Expedited Appeal of Delaware Court Finding that Nomination Notice was Properly Denied	AMEX:AIM	AIM ImmunoTech Inc
29/12/2023	10:15	Edgar (US Regulatory)	Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material	AMEX:AIM	AIM ImmunoTech Inc